Literature DB >> 31521603

Proteogenomic Network Analysis of Context-Specific KRAS Signaling in Mouse-to-Human Cross-Species Translation.

Douglas K Brubaker1, Joao A Paulo2, Shikha Sheth3, Emily J Poulin3, Olesja Popow4, Brian A Joughin5, Samantha Dale Strasser6, Alina Starchenko1, Steven P Gygi2, Douglas A Lauffenburger7, Kevin M Haigis8.   

Abstract

The highest frequencies of KRAS mutations occur in colorectal carcinoma (CRC) and pancreatic ductal adenocarcinoma (PDAC). The ability to target downstream pathways mediating KRAS oncogenicity is limited by an incomplete understanding of the contextual cues modulating the signaling output of activated K-RAS. We performed mass spectrometry on mouse tissues expressing wild-type or mutant Kras to determine how tissue context and genetic background modulate oncogenic signaling. Mutant Kras dramatically altered the proteomes and phosphoproteomes of preneoplastic and neoplastic colons and pancreases in a context-specific manner. We developed an approach to statistically humanize the mouse networks with data from human cancer and identified genes within the humanized CRC and PDAC networks synthetically lethal with mutant KRAS. Our studies demonstrate the context-dependent plasticity of oncogenic signaling, identify non-canonical mediators of KRAS oncogenicity within the KRAS-regulated signaling network, and demonstrate how statistical integration of mouse and human datasets can reveal cross-species therapeutic insights.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ASL; CDK2; KRAS; MET; SMAD3; cancer; colon; pancreas; phosphoproteomics; proteomics; species-translation

Year:  2019        PMID: 31521603      PMCID: PMC6816257          DOI: 10.1016/j.cels.2019.07.006

Source DB:  PubMed          Journal:  Cell Syst        ISSN: 2405-4712            Impact factor:   10.304


  56 in total

1.  Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry.

Authors:  Joshua E Elias; Steven P Gygi
Journal:  Nat Methods       Date:  2007-03       Impact factor: 28.547

2.  Target-decoy search strategy for mass spectrometry-based proteomics.

Authors:  Joshua E Elias; Steven P Gygi
Journal:  Methods Mol Biol       Date:  2010

3.  Integrated in vivo multiomics analysis identifies p21-activated kinase signaling as a driver of colitis.

Authors:  Jesse Lyons; Douglas K Brubaker; Phaedra C Ghazi; Katherine R Baldwin; Amanda Edwards; Myriam Boukhali; Samantha Dale Strasser; Lucia Suarez-Lopez; Yi-Jang Lin; Vijay Yajnik; Joseph L Kissil; Wilhelm Haas; Douglas A Lauffenburger; Kevin M Haigis
Journal:  Sci Signal       Date:  2018-02-27       Impact factor: 8.192

4.  Silencing of argininosuccinate lyase inhibits colorectal cancer formation.

Authors:  Hau-Lun Huang; Wei-Ching Chen; Hui-Ping Hsu; Chien-Yu Cho; Yu-Hsuan Hung; Chih-Yang Wang; Ming-Derg Lai
Journal:  Oncol Rep       Date:  2016-11-07       Impact factor: 3.906

5.  NDEx 2.0: A Clearinghouse for Research on Cancer Pathways.

Authors:  Dexter Pratt; Jing Chen; Rudolf Pillich; Vladimir Rynkov; Aaron Gary; Barry Demchak; Trey Ideker
Journal:  Cancer Res       Date:  2017-11-01       Impact factor: 12.701

6.  Rapid and reproducible single-stage phosphopeptide enrichment of complex peptide mixtures: application to general and phosphotyrosine-specific phosphoproteomics experiments.

Authors:  Arminja N Kettenbach; Scott A Gerber
Journal:  Anal Chem       Date:  2011-09-20       Impact factor: 6.986

7.  Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy" strategy.

Authors:  Cristina Basilico; Chiara Modica; Federica Maione; Elisa Vigna; Paolo M Comoglio
Journal:  Int J Cancer       Date:  2018-05-10       Impact factor: 7.396

8.  MicroRNA-34b inhibits pancreatic cancer metastasis through repressing Smad3.

Authors:  C Liu; H Cheng; S Shi; X Cui; J Yang; L Chen; P Cen; X Cai; Y Lu; C Wu; W Yao; Y Qin; L Liu; J Long; J Xu; M Li; X Yu
Journal:  Curr Mol Med       Date:  2013-05       Impact factor: 2.222

9.  KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma.

Authors:  Barbara Bournet; Fabrice Muscari; Camille Buscail; Eric Assenat; Marc Barthet; Pascal Hammel; Janick Selves; Rosine Guimbaud; Pierre Cordelier; Louis Buscail
Journal:  Clin Transl Gastroenterol       Date:  2016-03-24       Impact factor: 4.488

10.  Mouse Genome Database (MGD)-2017: community knowledge resource for the laboratory mouse.

Authors:  Judith A Blake; Janan T Eppig; James A Kadin; Joel E Richardson; Cynthia L Smith; Carol J Bult
Journal:  Nucleic Acids Res       Date:  2016-11-28       Impact factor: 16.971

View more
  15 in total

Review 1.  Towards targeting of shared mechanisms of cancer metastasis and therapy resistance.

Authors:  Felix Weiss; Douglas Lauffenburger; Peter Friedl
Journal:  Nat Rev Cancer       Date:  2022-01-10       Impact factor: 60.716

2.  MECHANISTIC AND DATA-DRIVEN MODELS OF CELL SIGNALING: TOOLS FOR FUNDAMENTAL DISCOVERY AND RATIONAL DESIGN OF THERAPY.

Authors:  Paul J Myers; Sung Hyun Lee; Matthew J Lazzara
Journal:  Curr Opin Syst Biol       Date:  2021-06-09

3.  Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention.

Authors:  Christian Johnson; Deborah L Burkhart; Kevin M Haigis
Journal:  Cancer Discov       Date:  2022-04-01       Impact factor: 38.272

4.  Integrated multi-omics characterization of KRAS mutant colorectal cancer.

Authors:  Wei Chong; Xingyu Zhu; Huicheng Ren; Chunshui Ye; Kang Xu; Zhe Wang; Shengtao Jia; Liang Shang; Leping Li; Hao Chen
Journal:  Theranostics       Date:  2022-07-04       Impact factor: 11.600

5.  An interspecies translation model implicates integrin signaling in infliximab-resistant inflammatory bowel disease.

Authors:  Douglas K Brubaker; Manu P Kumar; Evan L Chiswick; Cecil Gregg; Alina Starchenko; Paige N Vega; Austin N Southard-Smith; Alan J Simmons; Elizabeth A Scoville; Lori A Coburn; Keith T Wilson; Ken S Lau; Douglas A Lauffenburger
Journal:  Sci Signal       Date:  2020-08-04       Impact factor: 8.192

6.  Discovery of a selective inhibitor of doublecortin like kinase 1.

Authors:  Fleur M Ferguson; Behnam Nabet; Srivatsan Raghavan; Yan Liu; Alan L Leggett; Miljan Kuljanin; Radha L Kalekar; Annan Yang; Shuning He; Jinhua Wang; Raymond W S Ng; Rita Sulahian; Lianbo Li; Emily J Poulin; Ling Huang; Jost Koren; Nora Dieguez-Martinez; Sergio Espinosa; Zhiyang Zeng; Cesear R Corona; James D Vasta; Ryoma Ohi; Taebo Sim; Nam Doo Kim; Wayne Harshbarger; Jose M Lizcano; Matthew B Robers; Senthil Muthaswamy; Charles Y Lin; A Thomas Look; Kevin M Haigis; Joseph D Mancias; Brian M Wolpin; Andrew J Aguirre; William C Hahn; Kenneth D Westover; Nathanael S Gray
Journal:  Nat Chem Biol       Date:  2020-04-06       Impact factor: 15.040

Review 7.  Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers.

Authors:  Emily N Arner; Wenting Du; Rolf A Brekken
Journal:  Front Oncol       Date:  2019-10-11       Impact factor: 6.244

8.  EPHA2-dependent outcompetition of KRASG12D mutant cells by wild-type neighbors in the adult pancreas.

Authors:  William Hill; Andreas Zaragkoulias; Beatriz Salvador-Barbero; Geraint J Parfitt; Markella Alatsatianos; Ana Padilha; Sean Porazinski; Thomas E Woolley; Jennifer P Morton; Owen J Sansom; Catherine Hogan
Journal:  Curr Biol       Date:  2021-04-22       Impact factor: 10.834

9.  High expression of WTAP leads to poor prognosis of gastric cancer by influencing tumour-associated T lymphocyte infiltration.

Authors:  Huafu Li; Qiao Su; Bo Li; Linxiang Lan; Chunming Wang; Wuguo Li; Gangqiang Wang; Wei Chen; Yulong He; Changhua Zhang
Journal:  J Cell Mol Med       Date:  2020-03-16       Impact factor: 5.310

10.  KrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice.

Authors:  Jasmine C Wong; Pedro A Perez-Mancera; Tannie Q Huang; Jangkyung Kim; Joaquim Grego-Bessa; Maria Del Pilar Alzamora; Scott C Kogan; Amnon Sharir; Susan H Keefe; Carolina E Morales; Denny Schanze; Pau Castel; Kentaro Hirose; Guo N Huang; Martin Zenker; Dean Sheppard; Ophir D Klein; David A Tuveson; Benjamin S Braun; Kevin Shannon
Journal:  JCI Insight       Date:  2020-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.